As BTG2 upregulation is p53-dependent, particular focus should be dedicated to this transcript when designing p53-reactivating therapies and for further analysis of relationship to drug response and outcomes in patient cohorts with colorectal cancer. This evidence concerns the gene BTG2 and colorectal cancer.